Journal Article (Review Article)

DKFZ-2023-01542

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma.

Barbour, A. B. ; Kirste, S.DKFZ* ; Grosu, A.-L.DKFZ* ; Siva, S. ; Louie, A. V. ; Onishi, H. ; Swaminath, A. ; Teh, B. S. ; Psutka, S. P. ; Weg, E. S. ; Chen, J. J. ; Zeng, J. ; Gore, J. L. ; Hall, E. ; Liao, J. J. ; Correa, R. J. M. ; Lo, S. S.

2023
MDPI Basel

This record in other databases:  

Please use a persistent id in citations: doi:10.3390/cancers15143672

Abstract: Localized renal cell carcinoma is primarily managed surgically, but this disease commonly presents in highly comorbid patients who are poor operative candidates. Less invasive techniques, such as cryoablation and radiofrequency ablation, are effective, but require percutaneous or laparoscopic access, while generally being limited to cT1a tumors without proximity to the renal pelvis or ureter. Active surveillance is another management option for small renal masses, but many patients desire treatment or are poor candidates for active surveillance. For poor surgical candidates, a growing body of evidence supports stereotactic ablative radiotherapy (SABR) as a safe and effective non-invasive treatment modality. For example, a recent multi-institution individual patient data meta-analysis of 190 patients managed with SABR estimated a 5.5% five-year cumulative incidence of local failure with one patient experiencing grade 4 toxicity, and no other grade ≥3 toxic events. Here, we discuss the recent developments in SABR for the management of localized renal cell carcinoma, highlighting key concepts of appropriate patient selection, treatment design, treatment delivery, and response assessment.

Keyword(s): RCC ; SABR ; SBRT ; kidney cancer ; radiation oncology ; renal cancer ; renal carcinoma ; stereotactic body radiation therapy

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Freiburg (FR01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2023

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---